An institute has done thorough research on Sonnet BioTherapeutics (SONN) confirmed that it’s pipeline of assets on why Sonnet BioTherapeutics could create a treatment for COVID-19 coronavirus.
The institute states that the method they use could also be applied for other diseases and could practically work effectively.
The Fully Human Albumin Binding (FHAB) platform technology leverages a single chain antibody fragment (scFV) coupled with two flexible linker peptides that are capable of attaching to nearly any type of biologic or small molecule therapeutic where they also state that this technology has use for oncology and COVID-19.
Innate response is another way you can clear COVID-19, this clearing could potentially eliminate infected cells and the virus, stabilize humoral response and reduce inflammation by shifting macrophage into a healing mode.
Using Sonnet BioTherapeutics drug delivery platform this could very well be the best investment for COVID-19.
Sonnet BioTherapeutics (SONN) Skyrockets in Extended Hours
Yesterday SONN stock skyrocketed 66% on the news of a possible COVID-19 treatment by the research institute and may see more of the stock rising up as markets open tomorrow.
Altru Institute Launches Virus Project to Find Breakthrough Treatments
Altru Institute is the institution who choose Sonnet BioTherapeutics first as a research candidate. The sole purpose of this project is to find and publish studies that looks at unique COVID-19 possibilities and then publishes the research to seek input from scientists around the world.
